CN115461338B - 具有kdm5抑制活性的3-氮杂二环(3.1.0)己烷衍生物及其用途 - Google Patents

具有kdm5抑制活性的3-氮杂二环(3.1.0)己烷衍生物及其用途 Download PDF

Info

Publication number
CN115461338B
CN115461338B CN202180032139.2A CN202180032139A CN115461338B CN 115461338 B CN115461338 B CN 115461338B CN 202180032139 A CN202180032139 A CN 202180032139A CN 115461338 B CN115461338 B CN 115461338B
Authority
CN
China
Prior art keywords
azabicyclo
mmol
general formula
substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180032139.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN115461338A (zh
Inventor
角内章人
梅村周平
浅田正树
安纳托利.鲁文斯基
张艳
高桥秀典
哥伦.克里洛夫
猪山大吾
凯尔.康兹
麦兹.史文森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Publication of CN115461338A publication Critical patent/CN115461338A/zh
Application granted granted Critical
Publication of CN115461338B publication Critical patent/CN115461338B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180032139.2A 2020-05-07 2021-05-06 具有kdm5抑制活性的3-氮杂二环(3.1.0)己烷衍生物及其用途 Active CN115461338B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/088925 2020-05-07
CN2020088925 2020-05-07
PCT/CN2021/091843 WO2021223699A1 (en) 2020-05-07 2021-05-06 3-azabicyclo(3.1.0)hexane derivatives having kdm5 inhibitory activity and use thereof

Publications (2)

Publication Number Publication Date
CN115461338A CN115461338A (zh) 2022-12-09
CN115461338B true CN115461338B (zh) 2024-02-20

Family

ID=76159223

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180032139.2A Active CN115461338B (zh) 2020-05-07 2021-05-06 具有kdm5抑制活性的3-氮杂二环(3.1.0)己烷衍生物及其用途

Country Status (14)

Country Link
US (3) US11691968B2 (https=)
EP (2) EP4471027A1 (https=)
JP (3) JP7643466B2 (https=)
KR (2) KR20260046494A (https=)
CN (1) CN115461338B (https=)
AU (1) AU2021268223B2 (https=)
BR (1) BR112022022005A2 (https=)
CA (1) CA3181604A1 (https=)
ES (1) ES3037418T3 (https=)
IL (1) IL297900B2 (https=)
MX (1) MX2022013692A (https=)
NZ (1) NZ793960A (https=)
TW (1) TWI895412B (https=)
WO (1) WO2021223699A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3999183A4 (en) * 2019-07-17 2023-11-15 Ono Pharmaceutical Co., Ltd. COMPOUNDS HAVING KDM5 INHIBITANT ACTION AND THEIR PHARMACEUTICAL USES
ES3037418T3 (en) 2020-05-07 2025-10-01 Ono Pharmaceutical Co 3-azabicyclo(3.1.0)hexane derivatives having kdm5 inhibitory activity and use thereof
JP7743829B2 (ja) * 2021-11-05 2025-09-25 小野薬品工業株式会社 Ｋｄｍ５阻害作用を有する化合物を含有する医薬組成物
WO2025239445A1 (ja) * 2024-05-17 2025-11-20 小野薬品工業株式会社 認知症の行動および心理症状の予防、進行抑制および／または治療剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1331679A (zh) * 1998-12-23 2002-01-16 辉瑞大药厂 作为阿片受体配体的3－氮杂二环[3.1.0]己烷衍生物
WO2016057924A1 (en) * 2014-10-10 2016-04-14 Genentech, Inc. Pyrrolidine amide compounds as histone demethylase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0311859D0 (en) 2003-05-22 2003-06-25 Merck Sharp & Dohme Therapeutic agents
JP5017103B2 (ja) 2004-06-17 2012-09-05 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 薬剤共結晶組成物および関連した使用方法
JP2008524331A (ja) 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
RU2487127C2 (ru) 2007-10-09 2013-07-10 Ф.Хоффманн-Ля Рош Аг Хиральные цис-имидазолины
CN108341819B (zh) 2017-01-22 2021-06-15 南京药捷安康生物科技有限公司 磷酸二酯酶抑制剂及其用途
EP3999183A4 (en) 2019-07-17 2023-11-15 Ono Pharmaceutical Co., Ltd. COMPOUNDS HAVING KDM5 INHIBITANT ACTION AND THEIR PHARMACEUTICAL USES
ES3037418T3 (en) 2020-05-07 2025-10-01 Ono Pharmaceutical Co 3-azabicyclo(3.1.0)hexane derivatives having kdm5 inhibitory activity and use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1331679A (zh) * 1998-12-23 2002-01-16 辉瑞大药厂 作为阿片受体配体的3－氮杂二环[3.1.0]己烷衍生物
WO2016057924A1 (en) * 2014-10-10 2016-04-14 Genentech, Inc. Pyrrolidine amide compounds as histone demethylase inhibitors

Also Published As

Publication number Publication date
IL297900B2 (en) 2026-04-01
JP7643466B2 (ja) 2025-03-11
WO2021223699A1 (en) 2021-11-11
JP2023524547A (ja) 2023-06-12
IL297900B1 (en) 2025-12-01
CN115461338A (zh) 2022-12-09
IL297900A (en) 2023-01-01
US12269817B2 (en) 2025-04-08
EP4146645A1 (en) 2023-03-15
US20230271952A1 (en) 2023-08-31
TWI895412B (zh) 2025-09-01
CA3181604A1 (en) 2021-11-11
KR20260046494A (ko) 2026-04-07
TW202200571A (zh) 2022-01-01
JP7643632B2 (ja) 2025-03-11
JP2025081677A (ja) 2025-05-27
KR20230007352A (ko) 2023-01-12
AU2021268223B2 (en) 2025-10-09
AU2021268223A1 (en) 2022-12-08
US20250214984A1 (en) 2025-07-03
EP4471027A1 (en) 2024-12-04
BR112022022005A2 (pt) 2022-12-13
US20230109293A1 (en) 2023-04-06
JP2024177345A (ja) 2024-12-19
KR102937044B1 (ko) 2026-03-09
ES3037418T3 (en) 2025-10-01
EP4146645B1 (en) 2025-06-25
US11691968B2 (en) 2023-07-04
NZ793960A (en) 2025-12-19
MX2022013692A (es) 2022-11-30

Similar Documents

Publication Publication Date Title
CN115461338B (zh) 具有kdm5抑制活性的3-氮杂二环(3.1.0)己烷衍生物及其用途
JP6276277B2 (ja) Ｂｅｔタンパク質阻害性の５−アリールトリアゾロアゼピン
JP7786517B2 (ja) Ｋｄｍ５阻害活性を有する化合物およびその医薬用途
IL285246B2 (en) Substituted bicyclic compounds as farnesoid x receptor modulators
WO2015137385A1 (ja) ピリダジン化合物
JP2016514709A (ja) ヤヌスキナーゼ阻害剤としてのジェミナル置換シアノエチルピラゾロピリドン
MD3679034T2 (ro) Derivați 1-(4-(izoxazol-5-il)-1H-pirazol-1-il)-2-metilpropan-2-ol și compuși similari ca inhibitori IL-7 și IFN-gamma pentru tratarea bolilor autoimune și a inflamației cronice
CN116635028A (zh) c-MYC mRNA翻译调节剂及其在治疗癌症中的用途
RU2840256C1 (ru) Соединение, обладающее ингибирующей активностью в отношении kdm5, и его фармацевтическое применение
JP7743829B2 (ja) Ｋｄｍ５阻害作用を有する化合物を含有する医薬組成物
TWI907744B (zh) 包含具有kdm5抑制活性之化合物之醫藥組合物
KR20230065914A (ko) Kdm5 억제 활성을 갖는 화합물을 포함하는 약학 조성물
HK40083699A (en) 3-azabicyclo(3.1.0)hexane derivatives having kdm5 inhibitory activity and use thereof
HK40083699B (zh) 具有kdm5抑制活性的3-氮杂二环(3.1.0)己烷衍生物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40083699

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant